Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT00782275
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Vanderbilt Univeristy Medical Center, Nashville, Tennessee, United States
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2017-11-09
- Target Recruit Count
- 60
- Registration Number
- NCT00775593
- Locations
- 🇮🇹
Policlinico G. B. Rossi - Borgo Roma, Verona, Italy
🇮🇹Ospedale S. Eugenio, Roma, Italy
🇮🇹S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy
Erlotinib and Temsirolimus for Solid Tumors
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 46
- Registration Number
- NCT00770263
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Doxil, Bevacizumab and Temsirolimus Trial
- Conditions
- Interventions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00761644
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 73
- Registration Number
- NCT00729586
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00723255
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT00703625
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 28
- Registration Number
- NCT00703170
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1520
- Registration Number
- NCT00700258
- Locations
- 🇩🇪
Office of Detlef Muller, Bautzen, Germany
🇩🇪Klotz, Weiden, Germany
🇩🇪Carsten Lange, Bernburg, Germany
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00699491
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Methodist Medical Center of Illinois, Peoria, Illinois, United States
🇺🇸Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.